About Mallinckrodt Pharmaceuticals
Mallinckrodt Pharmaceuticals is a publicly listed company based in St. Louis (United States) founded in 1867, and was acquired by Tyco in June 2000. Specialty pharmaceutical products and diagnostic imaging agents are manufactured. The company has 2,700 employees. Mallinckrodt Pharmaceuticals has completed 9 acquisitions, including CNS Therapeutics, Ikaria and Ikaria Australia. Its website mallinckrodt.com draws about 32 thousand monthly visits. Mallinckrodt Pharmaceuticals offers products and services including Acthar® Gel and Specialty Generics. Its legal entity is Mallinckrodt plc.
Company details
Manufacturer of specialty pharmaceutical products and diagnostic imaging agents. It develops and markets and specialty pharmaceutical products, biopharmaceutical products, therapies, and nuclear imaging products. Areas of focus include autoimmune diseases and rare diseases in specialty areas like neurology, rheumatology, nephrology and pulmonology, immunotherapy and neonatal respiratory critical care therapies, analgesics, and hemostasis products, and central nervous system drugs. It claims to have received US FDA approvals for 14 products since 2010 and has almost 24 products in the pipeline at various stages of clinical trials for various diseases. An acquired subsidiary of the company Ikaria develops and commercializes critical care therapeutics and interventions designed to address the significant needs of critically ill patients. It offers an FDA-cleared inhaled nitric oxide- a drug to treat hypoxic respiratory failure (HRF) in term and near-term infants, and the INOMAX delivery system (FDA 510(k)- K090958).
- Headquarters St. Louis, United States
- Employees 2,700
- Stage Public
- Email••••••••
- Phone•••• ••••
- Website mallinckrodt.com
- Social LinkedIn X
- Acquired by Tyco (Jun 2000)
- Legal Name Mallinckrodt Plc
- Annual Revenue$166.2 M (USD)19as on Dec 31, 2024
- Net Profit$477.9 M (USD)1351as on Dec 31, 2024
- EBITDA$228.4 M (USD)1231as on Dec 31, 2024
- Latest Funding Round$26M (USD), Grant
Oct 2018
- InvestorsPiramal Group
& 2 more
- Employee Count2,700
- Investments & AcquisitionsCNS Therapeutics
& 8 more
- Acquired byTyco
(Jun 2000)
Products & Services of Mallinckrodt Pharmaceuticals
Mallinckrodt Pharmaceuticals offers a comprehensive portfolio of products and services, including Acthar® Gel and Specialty Generics.
This product is utilized for treating various medical conditions, with its development focused on improving patient outcomes through established formulation processes.
These are manufactured to provide affordable medical solutions, where distribution is handled to meet healthcare demands in compliance with industry standards.
Funding Insights of Mallinckrodt Pharmaceuticals
- Total Rounds 2
- Last Round Grant — $26M
- First Round $203M
(Jan 2017)
- Investors Count 2
All 2 funding rounds of Mallinckrodt Pharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2018 | $26M | Grant | – | – | |
| Jan 2017 | $203M | Post-IPO | – | – |
3 investors in total: 3 institutional.
Investors in Mallinckrodt Pharmaceuticals
Mallinckrodt Pharmaceuticals has secured backing from 3 investors, including institutional investors. Prominent investors backing the company include Piramal Group, Tyco and Public Health Emergency.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
| phe.gov | ||||
Multinational conglomerate with diverse interests in Pharma, Financial Services and Real Estate | 1984 | piramal.com | Mumbai, India | |
Fire, CCTV, and access control security solutions are provided. | 1960 | tyco.com | Princeton, United States |
Investor details for Mallinckrodt Pharmaceuticals
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Mallinckrodt Pharmaceuticals
172 people are tracked at Mallinckrodt Pharmaceuticals (55 in leadership, 4 in board & advisors, 113 in team); the tracked headcount is 2,700.
| Name | Role | Group |
|---|---|---|
Tina Costantini | Vice President Human Resources | Leadership |
Linda Green | Executive Assistant To The Evp, Chief Financial Officer & Vp, Fp&a At Mallinckrodt | Leadership |
Jaron Acker | Director Medical Device Marketing | Leadership |
Jae Han Park | Vice President / Head Of Specialty Generics R&d | Leadership |
David Phibbs | BI Business Partner | Leadership |
John Leonard | Sr. Site Director | Leadership |
Michael Leonardi | Associate Director, Business Intelligence | Leadership |
Olisaemeka Osefoh | Senior Director, Head Of Clinical Operations | Leadership |
Lori L Hamilton | Senior Executive Assistant To President And Ceo, Mark Trudeau | Leadership |
Adrian Williams | Director, National Accounts | Leadership |
Marianna Boyd | General Manager, Canada | Leadership |
Ron Hartmann | Director Project Engineering | Leadership |
Mark Puett | Sr. R&d Director | Leadership |
Andrea Canziani | Executive Director, Corporate Strategy | Leadership |
Ben Coleman | Sr. Director & Lead, Hospital Commercial Strategy (marketing) | Leadership |
Ron Brendel | R&d Director, Formulations At Mallinckrodt Pharmaceuticals | Leadership |
Ashley Brown | Regional Business Director | Leadership |
Sara Pirnstill | Sr. Director, Strategy And Business Excellence | Leadership |
Alasdair Fenlon | Senior Director Accounting | Leadership |
Christopher Puccio | Director, SEC Reporting & Accounting Policy | Leadership |
152 more people are available in the full profile.
Complete people profiles for Mallinckrodt Pharmaceuticals
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Mallinckrodt Pharmaceuticals
Mallinckrodt Pharmaceuticals has strategically engaged in corporate development activities, having acquired 9 companies. Notable acquisitions include CNS Therapeutics, Ikaria and Ikaria Australia.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Prostone-based drugs are developed for gastrointestinal, ophthalmic, and oncology disorders. | sucampo.com | Rockville, United States | 1996 | Dec 2017 | $1.2B | |
Ammonia scavenger drug for patients with acute and chronic liver disease | ocerainc.com | San Diego, United States | 2005 | Nov 2017 | •••• | |
Products for the neonatal and pediatric patient population | infacare.com | Feasterville Trevose, United States | 2001 | Sep 2017 | $425M | |
Cell-based skin substitutes are developed for therapeutic and research uses. | stratatechcorp.com | United States | 2000 | Aug 2016 | •••• | |
Therakos is focused on photopheresis systems for CTCL treatment. | therakos.com | West Chester, United States | 1984 | Aug 2015 | $1.33B | |
Developer of drug delivery system for treating cardiovascular disorders | ikariaaust.com | Kew, Australia | 2010 | Apr 2015 | $2.3B | |
Therapies for respiratory-related cardiopulmonary disorders are developed. | ikaria.com | Hampton, United States | 2005 | Mar 2015 | $2.3B | |
Biopharmaceutical treatments for autoimmune and inflammatory disorders are developed. | questcor.com | Anaheim, United States | 1990 | Apr 2014 | $5.8B | |
Biopharmaceuticals for spasticity and chronic pain are developed and supplied. | cnstherapeutics.com | Saint Paul, United States | 2007 | Sep 2012 | $100M |
Complete acquisition details for Mallinckrodt Pharmaceuticals
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Mallinckrodt Pharmaceuticals
14 dated milestones of Mallinckrodt Pharmaceuticals across 151 years, from founding to its latest funding, stage changes and deals.
- Founded Mallinckrodt Pharmaceuticals is founded.
- Exit Acquired by Tyco.
- Acquisition Acquires CNS Therapeutics.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires Questcor Pharmaceuticals.
- Acquisition Acquires Ikaria.
- Acquisition Acquires Ikaria Australia.
- Acquisition Acquires Therakos.
- Acquisition Acquires Stratatech Corp.
- Funding First funding round of $203.0M.
- Acquisition Acquires InfaCare Pharmaceuticals.
- Acquisition Acquires Ocera Therapeutics.
- Acquisition Acquires Sucampo.
- Funding Latest funding round, Grant, of $26.0M.
Web traffic of Mallinckrodt Pharmaceuticals
The website of Mallinckrodt Pharmaceuticals (mallinckrodt.com) receives about 31.9K visits a month.
- Monthly visits31.9K
▲ 40.1% vs previous month
Websites whose visitors overlap most with Mallinckrodt Pharmaceuticals. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| covidien.com | 100% | View details | |||
| boehringer-ingelheim.com | 96% | 1.6M | #39,825 | View details | |
| lilly.com | 92% | 4.9M | #13,252 | View details | |
| respironics.com | 85% | 6K | #3,213,822 | View details | |
almirall.es | almirall.es | 82% | #1,036,829 | – | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 40 similar websites and full traffic analytics for Mallinckrodt Pharmaceuticals
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 40 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Mallinckrodt Pharmaceuticals
Complete news archive for Mallinckrodt Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Mallinckrodt Pharmaceuticals
Mallinckrodt Pharmaceuticals was founded in 1867 and raised its 1st funding round 150 years after it was founded.
Mallinckrodt Pharmaceuticals is headquartered in St. Louis, United States. It is registered at St. Louis, Missouri, United States.
Mallinckrodt Pharmaceuticals has 2,700 employees.
Annual revenue of Mallinckrodt Pharmaceuticals is $166.2M as on Dec 31, 2024.
Manufacturer of specialty pharmaceutical products and diagnostic imaging agents. It develops and markets and specialty pharmaceutical products, biopharmaceutical products, therapies, and nuclear imaging products. Areas of focus include autoimmune diseases and rare diseases in specialty areas like neurology, rheumatology, nephrology and pulmonology, immunotherapy and neonatal respiratory critical care therapies, analgesics, and hemostasis products, and central nervous system drugs. It claims to have received US FDA approvals for 14 products since 2010 and has almost 24 products in the pipeline at various stages of clinical trials for various diseases. An acquired subsidiary of the company Ikaria develops and commercializes critical care therapeutics and interventions designed to address the significant needs of critically ill patients. It offers an FDA-cleared inhaled nitric oxide- a drug to treat hypoxic respiratory failure (HRF) in term and near-term infants, and the INOMAX delivery system (FDA 510(k)- K090958).
Mallinckrodt Pharmaceuticals offers Acthar® Gel and Specialty Generics.
Mallinckrodt Pharmaceuticals has made 9 acquisitions, including CNS Therapeutics, Ikaria, and Ikaria Australia.
Mallinckrodt Pharmaceuticals has 3 investors. Key investors include Piramal Group, Tyco, and Public Health Emergency.
Mallinckrodt Pharmaceuticals operates through Mallinckrodt Plc.
Yes. Mallinckrodt Pharmaceuticals was acquired by Tyco in June 2000.